Monday, October 8, 2012
XenoPort Inc., of Santa Clara, Calif., reported Phase I data testing four different oral formulations of XP23829, a fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF) and is in development for relapsing-remitting multiple sclerosis and/or psoriasis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.